Chloroquine-resistant falciparum malaria from Papua New Guinea and its implications for Australia.
There is need for effective chemoprophylaxis against chloroquine-resistant falciparum malaria, and for a safe and effective drug to be readily available for the treatment of that condition. Experience with the cases cited in this study indicates that Fansidar should be made available for treatment and it is suggested that Maloprim be made available as a prophylactic agent.
D000328:Adult; D001315:Australia; D002738:Chloroquine / Q000494:pharmacology / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D009512:New Guinea; D010963:Plasmodium falciparum / Q000187:drug effects; D011739:Pyrimethamine / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D013413:Sulfadoxine / Q000627:therapeutic use
D004338:Drug Combinations; D013413:Sulfadoxine; D002738:Chloroquine; D003622:Dapsone; D011803:Quinine; D011739:Pyrimethamine